Akciğer Adenokarsinom ve Skuamöz Hücreli Karsinomda [18F]FDG PET-BT 'de Lenf Nodu ve Dalak Aktivitesinin Prognostik Önemi
Amaç: Akciğer adenokanser ve skuamöz hücreli kanser tanısı alan hastalarda [18F]FDG PET-BT' de primer kitle, dalak ve lenf nodunun metabolik aktivitesinin prognostik değerininin yanısıra nötrofil lenfosit oranının (NLO) ve trombosit lenfosit oranının (TLO) prognostik değerlerini araştırmayı amaçladık. Yöntemler: Patolojik verilerine, tam kan sayımına ve [18F]FDG PET-BT görüntülerine ulaşılabilen 74 hasta retrospektif olarak değerlendirildi. Hastalar adenokarsinom (n = 32) veya skuamöz hücreli karsinom (n = 42) olarak gruplandırıldı. [18F]FDG PET-BT çekimi ile ölüme kadar geçen süre hesaplandı. Pimer lezyondan (akciğer veya mediasten ) standardized uptake value (SUVmax) hesaplandı. Dalağın SUVmax değeri, retiküloendotelyal sistem (RES) aktivitesinin bir göstergesi olarak kullanıldı. Lenf nodunun metabolik aktivitesi, lokalizasyondan bağımsız en yüksek aktiviteye sahip lenf nodundan hesaplandı. Bulgular: Skuamöz hücreli karsinom tanısı olup ölmüş olan grupta dalak/karaciğer SUVmax oranı ve lenf nodu/ karaciğer SUVmax oranları anlamlı derecede yüksekti (sırasıyla p = 0.025, p = 0.043) . Skuamöz hücreli karsinomda lenf nodu/karaciğer SUVmax oranının sağ kalım için belirleyici olduğu saptandı (p = 0.019, OR: 1.282). Dalak / karaciğer SUVmax ve lenf nodu / karaciğer SUVmax oranları adenokanserin alt grupları arasında benzerdi. Sonuç: Çalışmamızda dalaktaki SUV oranları her iki grupta da sağ kalım için bir belirteç değildi. Skuamöz hücreli karsinomda lenf nodu / karaciğer SUDmax oranının sağkalım için belirleyici bir faktör olduğu ancak NLO ve PLO' nun ise prognostik faktörler olmadığı görüldü.
Prognostic Value of Lymph Node and Spleen Activity in [18F]FDG PET-CT in Lung Adenocarcinoma and Squamous Cell Carcinoma
Objective: We aimed to investigate the prognostic value of primary mass, spleen and lymph node metabolic activity in[18F]FDG PET-CT as well as the prognostic value of neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio(TLR) in patients with lung adenocarcinoma and squamous cell carcinoma.Methods: Seventy-four patients, with pathological data, complete blood count and [18F]FDG PET-CT images, wereretrospectively evaluated. Patients were grouped as lung adenocarcinoma (n = 32) or squamous cell carcinoma (n =42). The time between [18F]FDG PET-CT imaging and death was calculated. Standardized uptake value (SUVmax) ofprimary lesion was calculated (lung or mediastinum). The SUVmax value of the spleen was used as an indicator of RESactivity. Metabolic activity of lymph node was calculated from the lymph node having the highest activity independentof localization.Results: The SUVmax spleen/liver and SUVmax lymph node/liver ratios were significantly higher in the exitussubgroup of squamous cell carcinoma (p=0.025, p=0.043; respectively). The SUVmax lymph node/liver ratio wasfound to be a predictor for survival in squamous cell carcinoma (p=0.019, OR:1.282). The SUVmax spleen/liver andSUVmax lymph node/liver ratios were similar between subgroups of adenocancer.Conclusions: The SUV ratios of the spleen were not a predictor for survival in both groups. The SUVmax lymphnode/liver ratio was found to be a predictor for survival in squamous cell carcinoma. However, NLR and PLR were notfound to be prognostic factors.
___
- Vansteenkiste J, Fischer BM, Dooms C, et all. Positron
emission tomography in prognostic and therapeutic
assessment of lung cancer: systematic review. Lancet
Oncol. 2004; 5: 531-40.
- de Geus-Oei LF, van Krieken JH, Aliredjo RP et all.
Biological correlates of FDG uptake in non-small cell
lung cancer. Lung Cancer. 2007; 55: 79-87.
- chuurbiers OC, Meijer TW, Kaanders JH, et all. Glucose
metabolism in NSCLC is histology-specific and diverges
the prognostic potential of 18FDG-PET for
adenocarcinoma and squamous cell carcinoma.. J
Thorac Oncol. 2014; 9: 1485-93.
- Lee HY, Lee HJ, Kim YT, et all. Value of combined
interpretation of computed tomography response and
positron emission tomography response for prediction
of prognosis after neoadjuvant chemotherapy in nonsmall
cell lung cancer. J Thorac Oncol. 2010; 5: 497-
503.
- Nair VS, Krupitskaya Y, Gould MK. Positron emission
tomography 18F fluorodeoxyglucose uptake and
prognosis in patients with surgically treated, stage I
non small cell lung cancer: a systematic review. J
Thorac Oncol. 2009;12: 1473-9.
- Lee JW, Na JO, Kang DY, Lee SY, Lee SM. Prognostic
Significance of FDG Uptake of Bone Marrow on PET/CT
in Patients With Non-Small-Cell Lung Cancer After
Curative Surgical Resection. Clin Lung Cancer. 2017;
18: 198-206.
- Prévost S, Boucher L, Larivée P, et all. Bone marrow
hypermetabolism on 18F-FDG PET as a survival
prognostic factor in non small cell lung cancer. 2006;
4:559-65.
- Blebea JS, Houseni M, Torigian DA, et all. Structural
and functional imaging of normal bone marrow and
evaluation of its age-related changes. Semin Nucl Med.
2007; 37:185-94.
- Wang J, Jia Y, Wang N, et all. The clinical significance of
tumor-infiltrating neutrophils and neutrophil-to- CD8+
lymphocyte ratio in patients with resectable
esophageal squamous cell carcinoma. J Transl Med.
2014; 12:7.
- Xue P, Kanai M, Mori Y, et al. Neutrophil-tolymphocyte
ratio for predicting palliative
chemotherapy outcomes in advanced pancreatic cancer
patients. Cancer Med. 2014; 3: 406-415.
- de Geus-Oei LF, van der Heijden H, Corstens F, et all.
Predictive and prognostic value of FDG-PET in
nonsmall-cell lung cancer. Cancer. 2007; 110: 1654-64.
- Al-Jahdali H, Khan AN, Loutfi S, et all. Guidelines for
the role of FDG-PET/CT in lung cancer management. J
Infect Public Health. 2012; 5: 35-40.
- Liu NB, Zhu L, Li MH, et all. Diagnostic value of 18FFDG
PET/CT in comparison to bone scintigraphy, CT
and 18F-FDG PET for the detection of bone metastasis.
Asian Pac J Cancer Prev. 2013; 14: 3647-52.
- Mutlu H, Buyukcelik A, Erden A, et all. Staging with
PET-CT in patients with locally advanced nonsmall cell
lung cancer is superior to conventional staging
methods in terms of survival. Asian Pac J Cancer Prev.
2013; 14: 3743-6.
- Motono N, Ueno M, Tanaka M, et all. Differences in the
prognostic significance of The SUVmax between
patients with resected pulmonary Adenocarcinoma and
squamous cell carcinoma. Asian Pac J Cancer Prev.
2014; 15: 10171-4.
- Vansteekiste JF, Stroobants SG, Dupont PJ, et all.
Prognostic importance of the standardized uptake
value on 18F-fluoro-2-deoxy-glucose-positron emission
tomography scan in non-small-cell lung cancer. An
analysis of 125 cases. J Clin Oncol. 1999; 17: 3201-6.
- Patz EF Jr, Connolly J, Herndon J. Prognostic value of
thoracic FDG PET imaging after treatment for nonsmall
cell lung cancer. AJR. 2000; 174: 769-74.
- Higashi K, Ueda Y, Arisaka Y, et all. 18F-FDG uptake as
a biologic prognostic factor for recurrence in patients
with surgically resected non-small cell lung cancer. J
Nucl Med. 2002; 43: 39-45.
- Jin F, Zhu H, Fu Z, Kong L, Yu J. Prognostic value of the
standardized uptake value maximum change calculated
by dual-time-point (18)F-fluorodeoxyglucose positron
emission tomography imaging in patients with
advanced non-small-cell lung cancer. Onco Targets
Ther. 2016; 19: 2993-9.
- Park JK, Kim JJ, Moon SW. Variations in positron
emission tomography-computed tomography findings
for patients receiving neo adjuvant and non-neo
adjuvant therapy for non-small cell lung cancer. J
Thorac Dis. 2017; 2: 344-54.
- Kraal G. Cells in the marginal zone of the spleen. Int
Rev Cytol. 1992; 132: 31-74.
- Nam HY, Kim SJ, Kim IJ, et all. The clinical implication
and prediction of diffuse splenic FDG uptake during
cancer surveillance. Clin Nucl Med. 2010; 35: 759-63.
- Pak K, Kim SJ, Kim IJ, et all. Impact of cytokines on
diffuse splenic 18F-fluorodeoxyglucose uptake during
positron emission tomography/computed tomography.
Nucl Med Commun. 2013; 34: 64-70.
- Salaun PY, Gastinne T, Bodet-Milin C, et all. Analysis
of 18F-FDG PET diffuse bone marrow uptake and
splenic uptake in staging of Hodgkin’s lymphoma: a
reflection of disease infiltration or just inflammation?
Eur J Nucl Med Mol Imaging. 2009; 36: 1813-21.
- Bural GG, Torigian DA, Chen W, et all. Increased 18FFDG
uptake within the reticuloendothelial system in
patients with active lung cancer on PET imaging may
indicate activation of the systemic immune response.
Hell J Nucl Med. 2010; 13: 23-5.
- Aktaş GE, Sarıkaya A, Demir SS. Diffusely Increased
Splenic Fluorodeoxyglucose Uptake in Lung Cancer
Patients. Turk Thorac J. 2017; 18: 6-10.
- Komek H, Altindag S and Can C. Association of PET
Scan Parameters of Pulmonary Masses and
Reticuloendothelial System with Hematologic
Parameters. J Nucl Med Radiat Ther. 2017; 8: 2.
- Nikolić I, Kukulj S, Samaržija M et all. Neutrophil-tolymphocyte
and platelet-to-lymphocyte ratio help
identify patients with lung cancer, but do not
differentiate between lung cancer subtypes. Croat Med
J. 2016; 3: 287-92.
- Gun XB, Tian T, Tian XJ et all. Prognostic significance
of neutrophil-to-lymphocyte ratio in non-small cell lung
cancer: ameta-analysis. Sci Rep. 2015; 5: 12493.
- Zhang H, Zhang L, Zhu K et all. Prognostic significance
of combination of preoperative platelet count and
neutrophil-lymphocyte ratio (COP-NLR) in patients
with non-small cell lung cancer: based on a large cohort
study. PLoS ONE. 2015; 10: e0126496.
- Unal D, Eroglu C, Kurtul N, et all. Are
neutrophil/lymphocyte and platelet/lymphocyte rates
in patients with non-small cell lung cancer associated
with treatment response and prognosis? Asian Pac J
Cancer Prev. 2013; 14: 5237-42.